NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Autor: Klümper N; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.; BRIDGE-Consortium Germany e.V., Mannheim, Germany., Tran NK; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany., Zschäbitz S; Department of Medical Oncology, National Center for Tumor Disease (NCT), University Hospital, Heidelberg, Germany., Hahn O; Department of Urology and Pediatric Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany., Büttner T; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany., Roghmann F; BRIDGE-Consortium Germany e.V., Mannheim, Germany.; Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany., Bolenz C; BRIDGE-Consortium Germany e.V., Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany., Zengerling F; BRIDGE-Consortium Germany e.V., Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany., Schwab C; Institute of Pathology, University of Heidelberg, Heidelberg, Germany., Nagy D; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.; Institute of Pathology, University Hospital Bonn, Bonn, Germany., Toma M; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.; Institute of Pathology, University Hospital Bonn, Bonn, Germany., Kristiansen G; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.; BRIDGE-Consortium Germany e.V., Mannheim, Germany.; Institute of Pathology, University Hospital Bonn, Bonn, Germany., Heers H; Department of Urology, University Hospital Marburg, Marburg, Germany., Ivanyi P; Department of Hemostaseology, Oncology and Stem Cell Transplantation, Medical University Hannover, Hannover, Germany., Niegisch G; Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany., Grunewald CM; Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany., Darr C; Department of Urology, University Hospital Essen, Essen, Germany., Farid A; Department of Urology, University Medical Center Göttingen, Göttingen, Germany., Schlack K; Department of Urology, University Hospital Münster, Münster, Germany., Abbas M; Department of Pathology, University Hospital Münster, Münster, Germany., Aydogdu C; Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany., Casuscelli J; Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany., Mokry T; Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany., Mayr M; Clinic Ottakring, Institute of Pathology and Microbiology, Wien, Austria., Niedersüß-Beke D; Department of Internal Medicine I, Wilhelminenspital, Wien, Austria., Rausch S; Department of Urology, Eberhard Karls University, Tübingen, Germany., Dietrich D; Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany., Saal J; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.; Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany., Ellinger J; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany., Ritter M; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.; BRIDGE-Consortium Germany e.V., Mannheim, Germany., Alajati A; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany., Kuppe C; Institute of Experimental Medicine and Systems Biology and Division of Nephrology, RWTH Aachen University, Aachen, Germany., Meeks J; Department of Urology, Feinberg School of Medicine, Chicago, IL., Vera Badillo FE; Department of Medical Oncology, Queen's University, Kingston, Ontario, Canada., Nakauma-González JA; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Boormans J; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Junker K; Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany., Hartmann A; BRIDGE-Consortium Germany e.V., Mannheim, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany., Grünwald V; Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany., Hölzel M; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany., Eckstein M; BRIDGE-Consortium Germany e.V., Mannheim, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jul 10; Vol. 42 (20), pp. 2446-2455. Date of Electronic Publication: 2024 Apr 24.

Book Notes

Autor: Rebelo, Ivona, Bonetti, Shane, Meeks, J. G. T., Johnes, Geraint, Steedman, Ian, Kennedy, Peter, Dow, Sheila C., Salisu, Mohammed Adaya, Massilia, Marzia Raybaudi, Redmond, John, Pilbeam, Keith, Bonetti, Shane, Ozawa, Terutoma, Berkouwer, J., Ghosh, Dipak, Morgan, Claire, Toivanen, Otto, Holmes, Mark J., Cohen, Ivan, Murinde, Victor, Myles, Gareth, Borooah, Vani, Barrientos, Armando, Siebert, W. S., Sicca, Renato, Liu, Minquan, Beesley, Michael, Trotter, Stephen, Tomlinson, B. R., Hall, Alastair, Stevens, Paul, Thoburn, John, Poyago-Theotoky, Joanna, Wright, Gavin, Alence, Rod, Morrissey, Oliver, Roberts, Jennifer, Teal, Francis, Harding, Rebecca, Kokko, Ari, Spash, Clive L., Markandya, A., Collins, Alan

Publikováno v: The Economic Journal, 1998 Jan 01. 108(446), 258-277.

Externí odkaz: https://www.jstor.org/stable/2565776

Degrees of Comment on Keynes on Uncertainty: Review Article on Keynes on Uncertainty and Tragic Happiness: Complexity and Expectations by Anna M. Carabelli.

Autor: Meeks, J Gay¹ (AUTHOR) jgm25@cam.ac.uk

Publikováno v: Contributions to Political Economy. Jul2023, Vol. 42 Issue 1, p6-26. 21p.

Investigating the subjective reports of rejection processes in the word frequency mirror effect

Autor: Meeks, J. Thadeus, Knight, Justin B., Brewer, Gene A., Cook, Gabriel I., Marsh, Richard L.

Publikováno v: In Consciousness and Cognition February 2014 24:57-69

1973P Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210

Autor: Guerrero-Ramos, F., Ku, J.H., Vilaseca, A., Raventos, C.X., Shore, N.D., Meeks, J., Li, R., Daneshmand, S., Jayram, G., Kang, T.W., Beeharry, N., Zhang, J., Weingeist, D., Smirnov, D.A., Brunton, B., Cost, C., Kalota, A., Lauring, J., Stone, N., Thomas, S.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S1143-S1143